Insomnia is a sleep-wake disorder characterized by difficulty in achieving or maintaining sleep, or early morning awakening for ≥3 nights per week for ≥3 months accompanied with daytime impairment.
The U.S. Food and Drug Administration recently approved aducanumab, the first treatment that aims to slow the progression of Alzheimer’s disease. But approval of the drug has provoked mixed reactions from the scientific community.
